Clinical Trials Logo

Clinical Trial Summary

It is a single-arm, open-label, multicenter, phase II clinical study to evaluate the clinical efficacy and safety of HLX10 monotherapy for the treatment of patients with unresectable or metastatic MSI-H or dMMR solid tumors who have progressed or intolerable after standard therapy.This study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria. The enrolled subjects will receive an intravenous infusion of HLX10 (3 mg/kg) once every 2 weeks until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent or other reasons as specified in the protocol, or up to the longest treatment duration-2 years (52 dosing periods) (whichever occurs earlier).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03941574
Study type Interventional
Source Shanghai Henlius Biotech
Contact ShuKui Qin
Phone 86-025-80864362
Email luolinhua0513@163.com
Status Recruiting
Phase Phase 2
Start date July 15, 2019
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04969887 - Combination Immunotherapy in Rare Cancers Under InvesTigation Phase 2
Recruiting NCT05086692 - A Beta-only IL-2 ImmunoTherapY Study Phase 1/Phase 2